Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

500

Employees500

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

500

Employees500

CORT Key Statistics

Market cap

4.19B

Market cap4.19B

Price-Earnings ratio

45.56

Price-Earnings ratio45.56

Dividend yield

—

Dividend yield—

Average volume

2.74M

Average volume2.74M

High today

$42.26

High today$42.26

Low today

$36.36

Low today$36.36

Open price

$37.39

Open price$37.39

Volume

5.07M

Volume5.07M

52 Week high

$117.33

52 Week high$117.33

52 Week low

$32.99

52 Week low$32.99

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $39.50, giving the company a market capitalization of 4.19B. It carries a P/E multiple of 45.56.

During the trading session on 2026-01-31, Corcept Therapeutics(CORT) shares reached a daily high of $42.26 and a low of $36.36. At a current price of $39.50, the stock is +8.6% higher than the low and still -6.5% under the high.

Trading volume for Corcept Therapeutics(CORT) stock has reached 5.07M, versus its average volume of 2.74M.

The stock's 52-week range extends from a low of $32.99 to a high of $117.33.

CORT News

TipRanks 21h

Corcept falls as FDA reveals it warned of CRL rejection for relacorilant

Shares of Corcept Therapeutics (CORT) were slipping after the FDA updated a Complete Response Letter for the company’s relacorilant capsules, with the FDA sayin...

Nasdaq 1d

Commit To Purchase Corcept Therapeutics At $25, Earn 18.7% Annualized Using Options

Investors eyeing a purchase of Corcept Therapeutics Inc (Symbol: CORT) stock, but tentative about paying the going market price of $39.61/share, might benefit f...

Simply Wall St 2d

Corcept Therapeutics Is Up 8.0% After ROSELLA Phase 3 Survival Gains - Has The Bull Case Changed?

Corcept Therapeutics recently reported that its pivotal Phase 3 ROSELLA trial showed relacorilant plus nab-paclitaxel improved both overall and progression-free...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

14.3%

Sell

14.3%

More CORT News

TipRanks 2d

Corcept’s TRIDENT Trial: Early Oncology Bet in Metastatic Pancreatic Cancer

Corcept Therapeutics (CORT) announced an update on their ongoing clinical study. Corcept Therapeutics is running a mid-stage (Phase 2) study called TRIDENT to...

TipRanks 3d

Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions

Corcept Therapeutics (CORT) announced an update on their ongoing clinical study. Study Overview This study, officially titled “A Phase 1b/2, Open-Label, Dose-...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Palantir Technologies

Robinhood Markets

Gilead Sciences

Vertex Pharmaceuticals

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.